StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) stock

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$10.41−1.33 (-11.33%)

Close on Nov 18, 2026Market cap $70.68MP/E –Yield –

Eloxx Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Eloxx Pharmaceuticals's revenue for the twelve months ending Jun 30, 2012 was $200.00K. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $6.36M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$6.36M–
FY2023Dec 31, 2023$0-100.0%
FY2014Jun 30, 2014$182.23K+2230.6%
FY2013Jun 30, 2013$7.82K-96.1%
FY2012Jun 30, 2012$200.00K+42.9%
FY2010Jun 30, 2010$140.00K–

More Eloxx Pharmaceuticals figures

See a number that looks wrong?